Caballero, AC, Escriba-Garcia, L, Alvarez-Fernandez, C, Briones, J. CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure. Frontiers in Immunology. 2022; 13DOI:10.3389/fimmu.2022.904497. PMID:35874685. IF:7.300(Q1/3D).

Perl, AE, Larson, RA, Podoltsev, NA, Strickland, S, Wang, ES, Atallah, E, Schiller, GJ, Martinelli, G, Neubauer, A, Sierra, J, Montesinos, P, Recher, C, Yoon, SS, Hosono, N, Onozawa, M, Chiba, S, Kim, HJ, Hasabou, N, Lu, QY, Tiu, R, Levis, MJ. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. BLOOD. 2022; 139(23)DOI:10.1182/blood.2021011583. PMID:35081255. IF:20.300(Q1/1D).

Tam, CS, Allan, JN, Siddiqi, T, Kipps, TJ, Jacobs, R, Opat, S, Barr, PM, Tedeschi, A, Trentin, L, Bannerji, R, Jackson, S, Kuss, BJ, Moreno, C, Szafer-Glusman, E, Russell, K, Zhou, C, Ninomoto, J, Dean, JP, Wierda, WG, Ghia, P. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. BLOOD. 2022; 139(22)DOI:10.1182/blood.2021014488. PMID:35196370. IF:20.300(Q1/1D).

Dreyling, M, Andre, M, Gokbuget, N, Tilly, H, Jerkeman, M, Gribben, J, Ferreri, A, Morel, P, Stilgenbauer, S, Fox, C, Ribera, JM, Zweegman, S, Aurer, I, Bodor, C, Burkhardt, B, Buske, C, Caballero, MD, Campo, E, Chapuy, B, Davies, A, de Leval, L, Doorduijn, J, Federico, M, Gaulard, P, Gay, F, Ghia, P, Gronbaek, K, Goldschmidt, H, Kersten, MJ, Kiesewetter, B, Landman-Parker, J, Le Gouill, S, Lenz, G, Leppa, S, Lopez-Guillermo, A, Macintyre, E, Mantega, MVM, Moreau, P, Moreno, C, Nadel, B, Okosun, J, Owen, R, Pospisilova, S, Pott, C, Robak, T, Spina, M, Stamatopoulos, K, Stary, J, Tarte, K, Tedeschi, A, Thieblemont, C, Trappe, RU, Trumper, LH, Salles, G. The EHA Research Roadmap: Malignant Lymphoid Diseases. Hemasphere. 2022; 6(6)DOI:10.1097/HS9.0000000000000726. PMID:35620592. IF:6.600(Q1/3D).

Waszczuk-Gajda, A, Penack, O, Sbianchi, G, Koster, L, Blaise, D, Remenyi, P, Russell, N, Ljungman, P, Trneny, M, Mayer, J, Iacobelli, S, Kobbe, G, Scheid, C, Apperley, J, Touzeau, C, Lenhoff, S, Jantunen, E, Anagnostopoulos, A, Paris, L, Browne, P, Thieblemont, C, Schaap, N, Sierra, J, Yakoub-Agha, I, Garderet, L, Styczynski, J, Schoemans, H, Moiseev, I, Duarte, RF, Peric, Z, Montoto, S, van Biezen, A, Mikulska, M, Aljurf, M, Ruutu, T, Kroger, N, Morris, C, Koenecke, C, Schoenland, S, Basak, GW. Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. Journal of Clinical Medicine. 2022; 11(12)DOI:10.3390/jcm11123541. PMID:35743620. IF:3.900(Q2/4D).

Pinana, JL, Lopez-Corral, L, Martino, R, Vazquez, L, Perez, A, Martin-Martin, G, Gago, B, Sanz-Linares, G, Sanchez-Salinas, A, Villalon, L, Conesa-Garcia, V, Olave, MT, Corona, M, Marcos-Corrales, S, Tormo, M, Hernandez-Rivas, JA, Montoro, J, Rodriguez-Fernandez, A, Risco-Galvez, I, Rodriguez-Belenguer, P, Hernandez-Boluda, JC, Garcia-Cadenas, I, Ruiz-Garcia, M, Munoz-Bellido, JL, Solano, C, Cedillo, A, Sureda, A, Navarro, D. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. Journal of Hematology & Oncology. 2022; 15(1)DOI:10.1186/s13045-022-01275-7. PMID:35526045. IF:28.500(Q1/1D).

Garcia-Fortes, M, Hernandez-Boluda, JC, Alvarez-Larran, A, Raya, JM, Angona, A, Estrada, N, Fox, L, Cuevas, B, Garcia-Hernandez, MC, Gomez-Casares, MT, Ferrer-Marin, F, Saavedra, S, Cervantes, F, Garcia-Delgado, R. Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis. Cancers. 2022; 14(9)DOI:10.3390/cancers14092331. PMID:35565461. IF:5.200(Q2/3D).

Arranz, MJ, Salazar, J, Bote, V, Artigas-Baleri, A, Serra-LLovich, A, Trivino, E, Roige, J, Lombardia, C, Cancino, M, Hernandez, M, Cendros, M, Duran-Tauleria, E, Maraver, N, Hervas, A. Pharmacogenetic Interventions Improve the Clinical Outcome of Treatment-Resistant Autistic Spectrum Disorder Sufferers. Pharmaceutics. 2022; 14(5)DOI:10.3390/pharmaceutics14050999. PMID:35631585. IF:5.400(Q1/2D).